Holen Sie sich die Stockscreener-App
0.38
8.61%
-0.0358
Vorhandelsmarkt:
.38
Schlusskurs vom Vortag:
$0.4158
Offen:
$0.4206
24-Stunden-Volumen:
638.91K
Relative Volume:
1.52
Marktkapitalisierung:
$14.81M
Einnahmen:
$7.06M
Nettoeinkommen (Verlust:
$-21.17M
KGV:
-0.3183
EPS:
-1.1939
Netto-Cashflow:
$-28.95M
1W Leistung:
-15.01%
1M Leistung:
-22.48%
6M Leistung:
-67.80%
1J Leistung:
-84.62%
1-Tages-Spanne:
$0.3784
$0.4206
1-Wochen-Bereich:
$0.3784
$0.4573
52-Wochen-Spanne:
$0.3784
$2.568
Curis Inc Stock (CRIS) Company Profile
Firmenname
Curis Inc
Sektor
Branche
Telefon
617-503-6500
Adresse
128 SPRING STREET, LEXINGTON, MA
Compare CRIS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
0.38 | 16.21M | 7.06M | -21.17M | -28.95M | -1.1939 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-11-17 | Eingeleitet | Truist | Buy |
| 2022-04-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2020-07-29 | Eingeleitet | Laidlaw | Buy |
| 2020-07-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2016-03-02 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-08-11 | Eingeleitet | FBR Capital | Outperform |
| 2015-01-22 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-21 | Bestätigt | ROTH Capital | Buy |
| 2014-05-09 | Bestätigt | Oppenheimer | Outperform |
| 2013-10-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2013-09-30 | Eingeleitet | Chardan Capital Markets | Buy |
| 2012-11-14 | Eingeleitet | Stifel Nicolaus | Hold |
| 2012-01-31 | Bestätigt | Brean Murray | Buy |
| 2012-01-31 | Bestätigt | Summer Street Research | Buy |
| 2011-12-09 | Eingeleitet | Oppenheimer | Outperform |
| 2011-10-06 | Eingeleitet | Summer Street Research | Buy |
| 2011-09-22 | Eingeleitet | MLV Capital | Buy |
| 2011-03-21 | Bestätigt | Brean Murray | Buy |
| 2010-02-26 | Bestätigt | Roth Capital | Buy |
| 2010-01-07 | Eingeleitet | Roth Capital | Buy |
Alle ansehen
Curis Inc Aktie (CRIS) Neueste Nachrichten
CRIS Q1 2026 Earnings: Deep EPS Miss Highlights Pre-Revenue Challenges Amid Strategic PivotQuarterly Earnings - newsline.com
Curis stock (US2312691006): Cancer biotech faces Nasdaq compliance deadline after reverse stock spli - AD HOC NEWS
Q1 2026 Curis Inc Earnings Call Transcript - GuruFocus
Curis (NASDAQ: CRIS) plans reverse stock split to address Nasdaq bid price - Stock Titan
CRIS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Curis Inc. (CRIS) Surges 8.33%: Momentum Builds Above Key SupportVolatility Stop - newsline.com
CRIS News | CURIS INC (NASDAQ:CRIS) - ChartMill
CRIS Q1 2026 Earnings: Significant EPS Miss Highlights Ongoing Pre-Revenue ChallengesEarnings Deceleration Risk - The Legal Advocate
CRIS Q1 2026 Earnings: Significant EPS Miss as Biotech Advances Pipeline Without RevenueRevenue Per Share - The Legal Advocate
Curis Inc. Q1 2026 Earnings: Deep EPS Miss as Pre-Revenue Biotech Continues DevelopmentShare Dilution Risk - Newser
CRIS Q1 2026 Earnings: Significant EPS Miss Amidst Operational UpdatesEPS Growth Rate - The Legal Advocate
Curis Shareholders Approve Expanded Capital Structure and Governance - TipRanks
Curis (NASDAQ: CRIS) wins shareholder approval to double authorized common stock - Stock Titan
Curis stock (US2312691006): Phase 1 data update lifts attention - AD HOC NEWS
Curis Inc Annual Shareholders Meeting Transcript - GuruFocus
CRIS: All five shareholder proposals, including director elections and share increase, were approved - TradingView
Curis to Host Webcast to Discuss Updated Emavusertib Clinical Da - GuruFocus
Curis Faces Nasdaq Delisting Determination, Plans Appeal Hearing - TipRanks
Why Curis (CRIS) Just Dropped -2.08% — What to Watch 2026-05-18Risk Reversal - The Legal Advocate
Curis stock (US2312691006): cancer pipeline update keeps investors cautious - AD HOC NEWS
Armistice Capital (NASDAQ: CRIS) reports 4.99% ownership of Curis - Stock Titan
JonesTrading Maintains Curis(CRIS.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Thomas Satterfield holds 3.96M shares as Curis (CRIS) ownership amended - Stock Titan
Curis, Inc. (NASDAQ:CRIS) Q1 2026 Earnings Call Transcript - Insider Monkey
Curis Q1 2026 earnings preview - MSN
Curis Inc. Earnings Call Highlights Clinical Momentum - TipRanks
Curis Q1 2026 Deep Dive: EPS Misses by 331.0%, Revenue Down 100% - AlphaStreet
Curis, Inc. (CRIS) Reports Q1 2026 Loss and Updates on Clinical Trials - GuruFocus
CURIS INC 1Q 2026: Revenue $0 Net income ($24.2M), EPS ($1.25) — 10-Q Summary - TradingView
Curis (NASDAQ: CRIS) posts larger Q1 2026 loss and warns on going concern - Stock Titan
Curis, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Curis anticipates TakeAim CLL initial 5-patient dosing by mid-2026 while projecting cash runway into second half of '27 - MSN
Curis Inc (CRIS) Q1 2026 Earnings Call Highlights: Progress in L - GuruFocus
Curis (CRIS) Expects Sufficient Funding to Support Operations Un - GuruFocus
Earnings call transcript: Curis Q1 2026 reveals widened net loss - Investing.com UK
Curis (CRIS) Reports Q1 Revenue Below Expectations - GuruFocus
Curis Q1 2026 Earnings Call Transcript - MarketBeat
Curis (CRIS) Q1 Miss: EPS -$1.25 vs -$0.40 est, Revenue $0 vs $1 - GuruFocus
Curis Provides First Quarter 2026 Business Update - GuruFocus
Curis Sees Cash Runway Into the 2H of 2027 >CRIS - Moomoo
Earnings call transcript: Curis Q1 2026 reveals widened net loss By Investing.com - Investing.com Nigeria
Curis Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Curis Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Curis reports Q1 loss, expects CLL trial milestone by mid-2026 - Investing.com South Africa
Finanzdaten der Curis Inc-Aktie (CRIS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):